Compositions and Uses for Treating Multiple Sclerosis

(19)

(11)

EP 2 137 537 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	01.06.2016 Bulletin 2016/22

(45)	Mention of the grant of the patent:
	29.05.2013 Bulletin 2013/22

(21)	Application number: 08725256.5

(22)	Date of filing: 07.02.2008

(51)

International Patent Classification (IPC):

A61K 31/225^(2006.01)
A61K 31/194^(2006.01)
A61K 31/277^(2006.01)
A61K 31/4704^(2006.01)
A61K 38/21^(2006.01)
G01N 33/50^(2006.01)

A61K 31/137^(2006.01)
A61K 31/197^(2006.01)
A61K 31/436^(2006.01)
A61K 31/7076^(2006.01)
A61K 45/06^(2006.01)

(86)	International application number:
	PCT/US2008/001602

(87)	International publication number:
	WO 2008/097596 (14.08.2008 Gazette 2008/33)

(54)	Compositions and Uses for Treating Multiple Sclerosis Zusammensetzungen und deren Verwendung zur Behandlung von Multipler Sklerosis Compositions et leurs utilisations pour le traitement de la Sclérose en plaques

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
	Designated Extension States:
	AL BA MK RS

(30)

Priority:

08.02.2007 US 888921 P

(43)	Date of publication of application:
	30.12.2009 Bulletin 2009/53

(60)	Divisional application:
	12169644.7 / 2518511
	13156663.0 / 2629097
	13169139.6 / 2653873
	13179016.4 / 2680006
	13179021.4 / 2680007
	13179023.0 / 2680008
	13179024.8 / 2680009
	13179025.5 / 2680010

(73)	Proprietor: Biogen MA Inc.
	Cambridge, MA 02142 (US)

(72)	Inventors:
	LUKASHEV, Matvey, E. Tewksbury, MA 01876 (US) O'NEILL, Gilmore Medford, MA 02155 (US)

(74)	Representative: Pohlman, Sandra M.
	df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte PartG mbB Theatinerstrasse 16 80333 München 80333 München (DE)

(56)

References cited: :

WO-A-2007/005879

WO-A2-2006/037342

SCHIMRIGK S ET AL: "Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study" EUROPEAN JOURNAL OF NEUROLOGY, vol. 13, no. 6, June 2006 (2006-06), pages 604-610, XP002496537 ISSN: 1351-5101
WIERINCKX ET AL: "Detoxication enzyme inducers modify cytokine production in rat mixed glial cells" JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 166, no. 1-2, 1 September 2005 (2005-09-01), pages 132-143, XP005000427 ISSN: 0165-5728
GOLD R ET AL: "Safety of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study", JOURNAL OF NEUROLOGY - ZEITSCHRIFT FUER NEUROLOGIE, SPRINGER VERLAG, BERLIN, DE, vol. 253, no. Suppl. 2, 1 May 2006 (2006-05-01), pages II144-II145, XP009157336, ISSN: 0340-5354


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).